High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: Results of the MOSCATO 01 trial

Cancer Discovery

Volumn 7, Issue 6, 2017, Pages 586-595

  Massard, Christophe ^a   Michiels, Stefan ^a,c   Ferté, Charles ^a   Le Deley, Marie Cécile ^a,c   Lacroix, Ludovic ^a,b,d   Hollebecque, Antoine ^a   Verlingue, Loic ^a   Ileana, Ecaterina ^a   Rosellini, Silvia ^a   Ammari, Samy ^a   Ngo Camus, Maud ^a   Bahleda, Rastislav ^a   Gazzah, Anas ^a   Varga, Andrea ^a   Postel Vinay, Sophie ^a   Loriot, Yohann ^a   Even, Caroline ^a   Breuskin, Ingrid ^a   Auger, Nathalie ^a   Job, Bastien ^a   De Baere, Thierry ^a   Deschamps, Frederic ^a   Vielh, Philippe ^a   Scoazec, Jean Yves ^a   Lazar, Vladimir ^a   Richon, Catherine ^a   Ribrag, Vincent ^a   Deutsch, Eric ^a,d   Angevin, Eric ^a   Vassal, Gilles ^a   Eggermont, Alexander ^a   André, Fabrice ^e   Soria, Jean Charles ^a   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e Universite Paris Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; BREAST CANCER; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; FUNCTIONAL GENOMICS; GENETIC ANALYSIS; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMOTHORAX; PROGRESSION FREE SURVIVAL; RNA SEQUENCE; STOMACH CANCER; TUMOR BIOPSY; URINARY TRACT CANCER; DISEASE FREE SURVIVAL; GENETICS; GENOMICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOPLASM; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85020241056     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-1396     Document Type: Article

References (32)

1. Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68: 3077-80; discussion 3080.
2. Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions. Cell 2012; 148: 409-20.
3. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
4. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-703.
5. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-8.
6. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
7. Iyer G, Hanrahan AJ, Milowsky MI, Al-Ahmadie H, Scott SN, Janakiraman M, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012; 338: 221.
8. Holderfield M, Deuker MM, McCormick F, McMahon M. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 2014; 14: 455-67.
9. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-75.
10. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015; 373: 726-36.
11. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
12. Swanton C, Soria JC, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, et al. Consensus on precision medicine for metastatic cancers: a report from the MAP conference. Ann Oncol 2016; 27: 1443-8.
13. Le Tourneau C, Delord JP, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol 2015; 16: 1324-34.
14. André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014; 15: 267-74.
15. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 2000; 21: 343-59.
16. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
17. Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28: 4877-83.
18. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011; 3: 111ra121.
19. Arnedos M, Scott V, Job B, De La Cruz J, Commo F, Mathieu MC, et al. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. Eur J Cancer 2012; 48: 2293-9.
20. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18: 6373-83.
21. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 2015; 33: 2753-62.
22. Beltran H, Eng K, Mosquera JM, Sigaras A, Romanel A, Rennert H, et al. Whole-exome sequencing of metastatic cancer and biomarkers of treatment response. JAMA Oncol 2015; 1: 466-74.
23. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner R, et al. Cancer therapy directed by comprehensive genomic profiling: A Single Center Study. Cancer Res 2016; 76: 3690-701.
24. Von Hoff DD. There are no bad anticancer agents, only bad clinical trial designs-twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 1998; 4: 1079-86.
25. Dufresne A, Pivot X, Tournigand C, Facchini T, Altweegg T, Chaigneau L, et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat 2008; 107: 275-9.
26. Buyse M, Quinaux E, Hendlisz A, Golfinopoulos V, Tournigand C, Mick R. Progression-free survival ratio as end point for phase II trials in advanced solid tumors. J Clin Oncol 2011; 29: e451-2.
27. Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA 3rd, Pritchard KI, et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from BOLERO-2. J Clin Oncol 2016; 34: 419-26.
28. André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, et al. Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol 2016; 34: 2115-24.
29. Postel-Vinay S, Boursin Y, Massard C, Hollebecque A, Ileana E, Chiron M, et al. Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?. Ann Oncol 2016; 27: 344-52.
30. Lazar V, Suo C, Orear C, van den Oord J, Balogh Z, Guegan J, et al. Integrated molecular portrait of non-small cell lung cancers. BMC Med Genomics 2013; 6: 53.
31. Lacroix L, Post SF, Valent A, Melkane AE, Vielh P, Egile C, et al. MET genetic abnormalities unreliable for patient selection for therapeutic intervention in oropharyngeal squamous cell carcinoma. PLoS One 2014; 9: e84319.
32. Andre F, Mardis E, Salm M, Soria JC, Siu LL, Swanton C. Prioritizing targets for precision cancer medicine. Ann Oncol 2014; 25: 2295-303.